Development and Validation of a Parsimonious Tuberculosis Gene Signature Using the digital NanoString nCounter Platform.

ABSTRACT:

Background

Blood-based biomarkers for diagnosing active tuberculosis (TB), monitoring treatment response, and predicting risk of progression to TB disease have been reported. However, validation of the biomarkers across multiple independent cohorts is scarce. A robust platform to validate TB biomarkers in different populations with clinical end points is essential to the development of a point-of-care clinical test. NanoString nCounter technology is an amplification-free digital detection platform that directly measures mRNA transcripts with high specificity. Here, we determined whether NanoString could serve as a platform for extensive validation of candidate TB biomarkers.

Methods

The NanoString platform was used for performance evaluation of existing TB gene signatures in

SUBMITTER: Kaipilyawar V 

PROVIDER: S-EPMC9522394 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature